Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer - Holmes, F A; O’Shaughnessy, J A; Vukelja, S; Jones, S E; Shogan, J; Savin, M; Glaspy, J; Moore, M; Meza, L; Wiznitzer, I; Neumann, T A; Hill, L R; Liang, B C (J Clin Oncol, 2002)
PM:11821454